147 related articles for article (PubMed ID: 8930051)
1. Professionals' perceptions of psychotropic medication in residential facilities for individuals with mental retardation.
Singh NN; Ellis CR; Donatelli LS; Williams DE; Ricketts RW; Goza AB; Perlman N; Everly DE; Best AM; Singh YN
J Intellect Disabil Res; 1996 Feb; 40 ( Pt 1)():1-7. PubMed ID: 8930051
[TBL] [Abstract][Full Text] [Related]
2. Psychopharmacological intervention. II: Teacher perceptions of psychotropic medication for students with learning disabilities.
Epstein MH; Singh NN; Luebke J; Stout CE
J Learn Disabil; 1991 Oct; 24(8):477-83. PubMed ID: 1940604
[TBL] [Abstract][Full Text] [Related]
3. Problem behavior and psychiatric impairment within a developmentally disabled population. III: Psychotropic medication.
Jacobson JW
Res Dev Disabil; 1988; 9(1):23-38. PubMed ID: 3353539
[TBL] [Abstract][Full Text] [Related]
4. Caregiver perceptions of psychotropic medication in residential facilities.
Aman MG; Singh NN; White AJ
Res Dev Disabil; 1987; 8(3):449-65. PubMed ID: 3671821
[TBL] [Abstract][Full Text] [Related]
5. Direct service staff and their perceptions of psychotropic medication in non-institutional settings for people with intellectual disability.
Christian L; Snycerski SM; Singh NN; Poling A
J Intellect Disabil Res; 1999 Apr; 43 ( Pt 2)():88-93. PubMed ID: 10221788
[TBL] [Abstract][Full Text] [Related]
6. The relationship between nurse characteristics and perceptions of psychotropic medications in residential facilities for the retarded.
Aman MG; Singh NN; Fitzpatrick J
J Autism Dev Disord; 1987 Dec; 17(4):511-23. PubMed ID: 3680153
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with psychotropic medication in mental retardation facilities.
Tu J; Smith JT
Compr Psychiatry; 1979; 20(3):289-95. PubMed ID: 446009
[No Abstract] [Full Text] [Related]
8. Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions.
Matson JL; Bielecki J; Mayville SB; Matson ML
Res Dev Disabil; 2003; 24(3):149-57. PubMed ID: 12742384
[TBL] [Abstract][Full Text] [Related]
9. Use of psychotropic medications for persons with mental retardation who live in Oklahoma nursing homes.
Spreat S; Conroy J
Psychiatr Serv; 1998 Apr; 49(4):510-2. PubMed ID: 9550242
[TBL] [Abstract][Full Text] [Related]
10. Practitioner versus medication-expert opinion on psychiatric pharmacotherapy of mentally retarded patients with mental disorders.
Patel NC; Crismon ML; Rush AJ; Frances A
Am J Health Syst Pharm; 2001 Oct; 58(19):1824-9. PubMed ID: 11596698
[TBL] [Abstract][Full Text] [Related]
11. Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings.
Clarke DJ; Kelley S; Thinn K; Corbett JA
J Ment Defic Res; 1990 Oct; 34 ( Pt 5)():385-95. PubMed ID: 2266549
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Psychiatric Practice Guidelines on Medication Costs and Youth Aggression in a Juvenile Justice Residential Treatment Program.
Lee TG; Walker SC; Bishop AS
Psychiatr Serv; 2016 Feb; 67(2):214-20. PubMed ID: 26423102
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Psychotropic Polypharmacy Among Outpatients With Psychiatric Disorders and Intellectual Disability.
Lunsky Y; Modi M
Psychiatr Serv; 2018 Feb; 69(2):242-246. PubMed ID: 29089006
[TBL] [Abstract][Full Text] [Related]
14. The international consensus process on psychopharmacology and intellectual disability.
Reiss S; Aman MG
J Intellect Disabil Res; 1997 Dec; 41 ( Pt 6)():448-55. PubMed ID: 9430048
[TBL] [Abstract][Full Text] [Related]
15. Proxy and self-reported Quality of Life in adults with intellectual disabilities: Impact of psychiatric symptoms, problem behaviour, psychotropic medication and unmet needs.
Koch AD; Vogel A; Becker T; Salize HJ; Voss E; Werner A; Arnold K; Schützwohl M
Res Dev Disabil; 2015; 45-46():136-46. PubMed ID: 26233765
[TBL] [Abstract][Full Text] [Related]
16. Mental health professionals' psychotropic pro re nata (p.r.n.) medication practices in acute inpatient mental health care: a qualitative study.
Baker JA; Lovell K; Harris N
Gen Hosp Psychiatry; 2007; 29(2):163-8. PubMed ID: 17336666
[TBL] [Abstract][Full Text] [Related]
17. Measurement of problem behaviour during medication evaluations.
Zarcone J; Napolitano D; Valdovinos M
J Intellect Disabil Res; 2008 Dec; 52(12):1015-28. PubMed ID: 18717764
[TBL] [Abstract][Full Text] [Related]
18. A survey of psychotropic medication in mental retardation facilities.
Tu JB
J Clin Psychiatry; 1979 Mar; 40(3):125-8. PubMed ID: 33967
[TBL] [Abstract][Full Text] [Related]
19. Knowledge and expectations of direct support professionals towards effects of psychotropic drug use in people with intellectual disabilities.
de Kuijper G; van der Putten AAJ
J Appl Res Intellect Disabil; 2017 Dec; 30 Suppl 1():1-9. PubMed ID: 28467003
[TBL] [Abstract][Full Text] [Related]
20. Informed consent for medication in persons with mental retardation and mental illness.
O'Sullivan JL; Borcherding BG
Health Matrix Clevel; 2002; 12(1):63-92. PubMed ID: 12013701
[No Abstract] [Full Text] [Related]
[Next] [New Search]
